The Lancet Diabetes & Endocrinology最新文献

{"title":"Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials","authors":"Sarah Kanbour, Rwedah A Ageeb, Rayaz A Malik, Laith J Abu-Raddad","doi":"10.1016/s2213-8587(24)00346-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00346-2","url":null,"abstract":"<h3>Background</h3>Bodyweight loss is associated with type 2 diabetes remission; however, the quantitative relationship between the degree of bodyweight loss and the likelihood of remission, after controlling for confounding factors, remains unknown. We aimed to analyse the relationship between the degree of bodyweight loss and diabetes remission after controlling for various confounding factors, and to provide estimates for the effect sizes of these factors on diabetes remission.<h3>Methods</h3>This systematic review and meta-regression analysis followed Cochrane and PRISMA guidelines to systematically review, synthesise, and report global evidence from randomised controlled trials done in individuals with type 2 diabetes and overweight or obesity. The outcome was the proportion of participants with complete diabetes remission (HbA<sub>1c</sub> <6·0% [42 mmol/mol] or fasting plasma glucose [FPG] <100 mg/dL [5·6 mmol/L], or both, with no use of glucose-lowering drugs) or partial diabetes remission (HbA<sub>1c</sub> <6·5% [48 mmol/mol] or FPG <126 mg/dL [7·0 mmol/L], or both, with no use of glucose-lowering drugs) at least 1 year after a bodyweight loss intervention. We searched PubMed, Embase, and trial registries from database inception up to July 30, 2024. Data were extracted from published reports. Meta-analyses and meta-regressions were performed to analyse the data. The study protocol is registered with PROSPERO (CRD42024497878).<h3>Findings</h3>We identified 22 relevant publications, encompassing 29 outcome measures of complete diabetes remission and 33 outcome measures of partial remission. The pooled mean proportion of participants with complete remission 1 year after the intervention was 0·7% (95% CI 0·1–4·6) in those with bodyweight loss less than 10%, 49·6% (40·4–58·9) in those with bodyweight loss of 20–29%, and 79·1% (68·6–88·1) in those with bodyweight loss of 30% or greater; no studies reported on complete remission with 10–19% bodyweight loss. The pooled mean proportion of participants with partial remission 1 year after the intervention was 5·4% (95% CI 2·9–8·4) in those with bodyweight loss less than 10%, 48·4% (36·1–60·8) in those with 10–19% bodyweight loss, 69·3% (55·8–81·3) in those with bodyweight loss of 20–29%, and 89·5% (80·0–96·6) in those with bodyweight loss of 30% or greater. There was a strong positive association between bodyweight loss and remission. For every 1 percentage point decrease in bodyweight, the probability of reaching complete remission increased by 2·17 percentage points (95% CI 1·94–2·40) and the probability of reaching partial remission increased by 2·74 percentage points (2·48–3·00). No significant or appreciable associations were observed between age, sex, race, diabetes duration, baseline BMI, HbA<sub>1c</sub>, insulin use, or type of bodyweight loss intervention and remission. Overall, data were derived from randomised controlled trials with a low risk of bias in all quality domains.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"6 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143507051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Type 1 diabetes screening: need for ethical, equity, and health systems perspective","authors":"David Beran, Aude Bandini, Emanuele Bosi, Claudia Boettcher, Marie-Anne Burckhard, Matthieu Colange, Nina Tousch, Valérie Schwitzgebel","doi":"10.1016/s2213-8587(25)00029-4","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00029-4","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"24 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Thank you to The Lancet Diabetes & Endocrinology's statistical and peer reviewers in 2024","authors":"","doi":"10.1016/s2213-8587(25)00035-x","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00035-x","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"32 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2025; 13: 221–62","authors":"","doi":"10.1016/s2213-8587(25)00006-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00006-3","url":null,"abstract":"<em>Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity.</em> Lancet Diabetes Endocrinol <em>2025; <strong>13:</strong> 221–62</em>—In this Commission, “Malaysian Association for the Study of Obesity (MASO) | Malaysia”, “Obesity Canada | Canada”, and “Sociedade Brasileira de Endocrinologia e Metabolismo (SBEM) | Brasil” should be present in Appendix 2 (Appendix 2.1 Table 1. Organisations that have endorsed the consensus statements of the commission), and the rest of the table subsequently renumbered. Consequently, the final sentence of the Executive summary in the Commission should say “endorsed by more than 75 organisations worldwide”. A Korean translation has been added to Appendix 1 and thus the list of translation languages for the Commission should be “Arabic, Chinese, French, German, Greek, Hindi, Italian, Japanese, Korean, Polish, Portuguese, Spanish, and Swedish”. These corrections have been made to the online version as of Feb 25, 2025, and the printed version is correct.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"49 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mpox and diabetes: a needed public health research agenda","authors":"Jennifer Manne-Goehler, Rosamund Lewis, Bianca Hemmingsen","doi":"10.1016/s2213-8587(25)00030-0","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00030-0","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"24 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143495822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D and acute respiratory infections: a definitive answer?","authors":"Chris Gallagher","doi":"10.1016/s2213-8587(24)00398-x","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00398-x","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"47 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D supplementation to prevent acute respiratory infections: systematic review and meta-analysis of stratified aggregate data","authors":"David A Jolliffe, Carlos A Camargo, John D Sluyter, Mary Aglipay, John F Aloia, Peter Bergman, Heike A Bischoff-Ferrari, Arturo Borzutzky, Vadim Y Bubes, Camilla T Damsgaard, Francine M Ducharme, Gal Dubnov-Raz, Susanna Esposito, Davaasambuu Ganmaa, Clare Gilham, Adit A Ginde, Inbal Golan-Tripto, Emma C Goodall, Cameron C Grant, Christopher J Griffiths, Adrian R Martineau","doi":"10.1016/s2213-8587(24)00348-6","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00348-6","url":null,"abstract":"<h3>Background</h3>A 2021 meta-analysis of 37 randomised controlled trials (RCTs) of vitamin D supplementation for prevention of acute respiratory infections (ARIs) revealed a statistically significant protective effect of the intervention (odds ratio [OR] 0·92 [95% CI 0·86 to 0·99]). Since then, six eligible RCTs have been completed, including one large trial (n=15 804). We aimed to re-examine the link between vitamin D supplementation and prevention of ARIs.<h3>Methods</h3>Updated systematic review and meta-analysis of data from RCTs of vitamin D for ARI prevention using a random effects model. Subgroup analyses were done to determine whether effects of vitamin D on risk of ARI varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration, dosing regimen, or age. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science, and the <span><span>ClinicalTrials.gov</span><svg aria-label=\"Opens in new window\" focusable=\"false\" height=\"20\" viewbox=\"0 0 8 8\"><path d=\"M1.12949 2.1072V1H7V6.85795H5.89111V2.90281L0.784057 8L0 7.21635L5.11902 2.1072H1.12949Z\"></path></svg></span> between May 1, 2020 (end-date of search of our previous meta-analysis) and April 30, 2024. No language restrictions were imposed. Double-blind RCTs supplementing vitamin D for any duration, with placebo or lower-dose vitamin D control, were eligible if approved by a Research Ethics Committee and if ARI incidence was collected prospectively and pre-specified as an efficacy outcome. Aggregate data, stratified by baseline 25(OH)D concentration and age, were obtained from study authors. The study was registered with PROSPERO (no. CRD42024527191).<h3>Findings</h3>We identified six new RCTs (19 337 participants). Data were obtained for 16 085 (83·2%) participants in three new RCTs and combined with data from 48 488 participants in 43 RCTs identified in our previous meta-analysis. For the primary comparison of any vitamin D versus placebo, the intervention did not statistically significantly affect overall ARI risk (OR 0·94 [95% CI 0·88–1·00], p=0·057; 40 studies; 61 589 participants; I²=26·4%). Pre-specified subgroup analysis did not reveal evidence of effect modification by age, baseline vitamin D status, dosing frequency, or dose size. Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (OR 0·96 [95% CI 0·90–1·04]; 38 studies; I²=0·0%). A funnel plot showed left-sided asymmetry (p=0·0020, Egger's test).<h3>Interpretation</h3>This updated meta-analysis yielded a similar point estimate for the overall effect of vitamin D supplementation on ARI risk to that obtained previously, but the 95% CI for this effect estimate now includes 1·00, indicating no statistically significant protection.<h3>Funding</h3>None.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"47 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to Lancet Diabetes Endocrinol 2024; 12: 523–34","authors":"","doi":"10.1016/s2213-8587(25)00051-8","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00051-8","url":null,"abstract":"<em>Eckard AR, Wu Q, Sattar A, et al. Once-weekly semaglutide in people with HIV-associated lipohypertrophy: a randomised, double-blind, placebo-controlled phase 2b single-centre clinical trial.</em> Lancet Diabetes Endocrinol <em>2024;</em> 12: <em>523–34</em>—In table 1, the number of participants in the placebo group listed as currently using tenofovir alafenamide has been corrected to 37 (69%). In the second paragraph of the results section, the fourth sentence has been corrected to, “80 (74%) of participants were on tenofovir alafenamide; 66 (61%) participants were on INSTI and tenofovir alafenamide.” In table 2, the subheadings have been corrected to: ln fasting insulin, uIU/mL; ln fasting HOMA-IR; In high-density lipoprotein cholesterol, mg/dL; In very low-density lipoprotein cholesterol, mg/dL; and ln triglycerides, mg/dL. Also in table 2, for the subheading ln atherosclerotic cardiovascular disease risk estimate; the β* value has been corrected to −0·39, the SE to 0·18, the 95% CI of β to −0·74 to −0·05, the p value to 0·0264‡, and the % change† to –32·6%. In the seventh paragraph of the results section, the second sentence has been corrected to, “Diastolic blood pressure, heart rate, total cholesterol, low-density lipoprotein cholesterol, caloric intake, and physical activity did not show any statistically significant changes.” The last two sentences of the seventh paragraph of the discussion have been removed. These changes have been made to the online version as of Feb 21, 2025.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"30 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"When glucose time in range is not tight, is it lax? Considering new terminology for CGM targets","authors":"Ray Wang, Mervyn Kyi, David O'Neal, Gerry Rayman, Spiros Fourlanos","doi":"10.1016/s2213-8587(25)00031-2","DOIUrl":"https://doi.org/10.1016/s2213-8587(25)00031-2","url":null,"abstract":"No Abstract","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"49 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143451492","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Realigning diabetes regimens in older adults: a 4S Pathway to guide simplification and deprescribing strategies","authors":"Medha Munshi, Anna R Kahkoska, Joshua J Neumiller, Anastasia-Stefania Alexopoulos, Nancy A Allen, Tali Cukierman-Yaffe, Elbert S Huang, Sei J Lee, Kasia J Lipska, Lisa M McCarthy, Graydon S Meneilly, Naushira Pandya, Richard E Pratley, Leocadio Rodriguez-Mañas, Alan J Sinclair, Sarah L Sy, Elena Toschi, Ruth S Weinstock","doi":"10.1016/s2213-8587(24)00372-3","DOIUrl":"https://doi.org/10.1016/s2213-8587(24)00372-3","url":null,"abstract":"Treating older people with diabetes is challenging due to multiple medical comorbidities that might interfere with patients' ability to perform self-care. Most diabetes guidelines focus on improving glycaemia through addition of medications, but few address strategies to reduce medication burden for older adults—a concept known as deprescribing. Strategies for deprescribing might include stopping high-risk medications, decreasing the dose, or substituting for less harmful agents. Accordingly, glycaemic management strategies for older adults with type 1 and type 2 diabetes not responding to their current regimen require an understanding of how and when to realign therapy to meet patient's current needs, which represents a major clinical practice gap. With the gap in guidance on how to deprescribe or otherwise adjust therapy in older adults with diabetes in mind, the International Geriatric Diabetes Society, an organisation dedicated to improving care of older individuals with diabetes, convened a Deprescribing Consensus Initiative in May, 2023, to discuss Optimization of diabetes treatment regimens in older adults: the role of de-prescribing, de-intensification and simplification of regimens. The recommendations from this group initiative are discussed and described in this Review.","PeriodicalId":48790,"journal":{"name":"The Lancet Diabetes & Endocrinology","volume":"64 1","pages":""},"PeriodicalIF":44.5,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143435485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}